Abstract
We present a cytogenetically normal neonate who developed transient abnormal myelopoiesis. The blasts showed trisomy 21. In contrast, fibroblasts, and PHA-stimulated peripheral blood demonstrated normal diploid line on extensive karyotyping. Direct sequencing of the DNA derived from the peripheral blood at overt disease revealed splice site mutation in the boundary of GATA1 exon 2. The patient received three courses of chemotherapy leading to complete remission. During the complete remission, there was neither mutation of GATA1 exon 2 nor trisomy 21, confirming somatic nature of both abnormalities. The patient is now free from the disease 12 months after remission. This case emphasizes the significance of trisomy 21 as the cause of transient abnormal myelopoiesis in Down syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392–9.
Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.
Cabelof DC, Patel HV, Chen Q, et al. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood. 2009;114:2753–63.
Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103:3242–3.
Richards M, Welch J, Watmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed. 1998;79:F215–7.
Polski JM, Galambos C, Gale GB, et al. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol. 2002;24:50–4.
Apollonsky N, Shende A, Ouansafi I, et al. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes. J Pediatr Hematol Oncol. 2008;30:860–4.
Sandoval C, Pine SR, Guo Q, et al. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer. 2005;44:85–91.
Cushing T, Clericuzio CL, Wilson CS, et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr. 2006;148:687–9.
Carpenter E, Valverde-Garduno V, Sternberg A, et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548–51.
Magalhães IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. 2005;27:50–2.
Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–6.
Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA. 2001;98:5776–9.
Hoskote A, Chessells J, Pierce C. Transient abnormal myelopoiesis (TAM) causing multiple organ failure. Intensive Care Med. 2002;28:758–62.
Schwab M, Niemeyer C, Schwarzer U. Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. Med Pediatr Oncol. 1998;31:159–65.
Rizzari C, Malberti R, Dell’Orto M, et al. Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems? Med Pediatr Oncol. 1999;32:453–4.
Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112:4503–6.
Groet J, Mulligan C, Spinelli M, et al. Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. Blood. 2005;106:1887–8.
Kanegane H, Watanabe S, Nomura K, et al. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. Int J Hematol. 2007;86:250–2.
Hellebostad M, Carpenter E, Hasle H, Mitchell C, Vyas P. GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis. J Pediatr Hematol Oncol. 2005;27:408–9.
Acknowledgments
We thank Dr. Alan H. Turner, School of Medical Sciences, RMIT University, Melbourne, Australia and Ms. Yuko Kasai for reviewing the manuscript. This work was supported by Ibaraki Cancer Investigation Fund.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yanase, K., Kato, K., Katayama, N. et al. Transient abnormal myelopoiesis in a cytogenetically normal neonate. Int J Hematol 92, 527–530 (2010). https://doi.org/10.1007/s12185-010-0646-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-010-0646-1